<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DORMOSEDAN  STERILE- detomidine hydrochloride solution </strong><br>Zoetis Inc.<br></p></div>
<h1>DORMOSEDAN<span class="Sup">®</span><br>(detomidine hydrochloride)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Italics">Sedative and Analgesic For Use in Horses Only</span></p>
<p><span class="Italics">Sterile Solution<br>10mg/mL</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">CAUTION: </span>Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<p class="First"><span class="Bold">DESCRIPTION:</span> Dormosedan® is a synthetic alpha-2 adrenoreceptor agonist with sedative and analgesic properties. The chemical name is 1H imidazole, 4-[(2,3-dimethylphenyl) methyl]- hydrochloride and the generic name is detomidine hydrochloride. It is a white, crystalline, water-soluble substance having a molecular weight of 222.7. The molecular formula is C<span class="Sub">12</span>H<span class="Sub">14</span>N<span class="Sub">2</span>∙HCl.</p>
<p><span class="Bold">CHEMICAL STRUCTURE:</span></p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0effd774-601f-4019-a1f3-350e47835967&amp;name=dormosedan-01.jpg"></div>
<p>Each mL of Dormosedan® contains 10.0 mg detomidine hydrochloride, 1.0 mg methyl paraben, 5.9 mg sodium chloride, and water for injection, q.s.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-4"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY: </span> Dormosedan®, a non-narcotic sedative and analgesic, is a potent α<span class="Sub">2</span>-adrenoreceptor agonist which produces sedation and superficial and visceral <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> which is dose dependent in its depth and duration. Profound <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> and a characteristic lowering of the head with reduced sensitivity to environmental stimuli (sounds, etc.) are seen with detomidine. A short period of <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span> is characteristically followed by immobility and a firm stance with front legs well spread. The <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> is most readily seen as an increase in the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> threshold at the body surface. Sensitivity to touch is little affected and in some cases may actually be enhanced.</p>
<p>With detomidine administration, heart rate is markedly decreased, blood pressure is initially elevated, and then a steady decline to normal is seen. A transient change in the conductivity of the cardiac muscle may occur, as evidenced by partial atrioventricular (AV) and sinoauricular (SA) blocks. This change in the conductivity of the cardiac muscle may be prevented by IV administration of atropine at 0.02 mg/kg of body weight.</p>
<p>No effect on blood clotting time or other hematological parameters was encountered at dosages of 20 or 40 mcg/kg of body weight. Respiratory responses include an initial slowing of respiration within a few seconds to 1–2 minutes after administration, increasing to normal within 5 minutes. An initial decrease in tidal volume is followed by an increase.</p>
</div>
<div class="Section" data-sectionCode="50745-9">
<a name="section-5"></a><p></p>
<p class="First"><span class="Bold">INDICATIONS: </span>Dormosedan® is indicated for use as a sedative and analgesic to facilitate minor surgical and diagnostic procedures in mature horses and yearlings. It has been used successfully for the following: to calm fractious horses, to provide relief from <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, to facilitate bronchoscopy, bronchoalveolar lavage, nasogastric intubation, nonreproductive rectal palpations, suturing of <span class="product-label-link" type="condition" conceptid="4148390" conceptname="Laceration">skin lacerations</span>, and castrations. Additionally, an approved, local infiltration anesthetic is indicated for castration.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS: </span>Dormosedan® should not be used in horses with pre-existing AV or SA block, with severe coronary insufficiency, cerebrovascular disease, respiratory disease, or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>. Intravenous potentiated sulfonamides should not be used in anesthetized or sedated horses as potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> may occur.</p>
<p>Information on the possible effects of detomidine hydrochloride in breeding horses is limited to uncontrolled clinical reports; therefore, this drug is not recommended for use in breeding animals.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<p class="First"><span class="Bold">WARNINGS: Do not use in horses intended for human consumption. Not for human use. Keep out of reach of children.</span></p>
</div>
<div class="Section" data-sectionCode="50741-8">
<a name="section-8"></a><p></p>
<p class="First"><span class="Bold">HUMAN SAFETY INFORMATION: </span>Care should be taken to assure that detomidine hydrochloride is not inadvertently ingested as safety studies have indicated that the drug is well absorbed when administered orally. Standard ocular irritation tests in rabbits using the proposed market formulation have shown detomidine hydrochloride to be nonirritating to eyes. Primary dermal irritation tests in guinea pigs using up to 5 times the proposed market concentration of detomidine hydrochloride on intact and abraded skin have demonstrated that the drug is nonirritating to skin and is apparently poorly absorbed dermally. However, in accordance with prudent clinical procedures, exposure of eyes or skin should be avoided and affected areas should be washed immediately if exposure does occur. As with all injectable drugs causing profound physiological effects, routine precautions should be employed by practitioners when handling and using loaded syringes to prevent accidental self-injection.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-9"></a><p></p>
<p class="First"><span class="Bold">PRECAUTIONS: </span>Before administration, careful consideration should be given to administering Dormosedan® to horses approaching or in endotoxic or traumatic <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, to horses with advanced liver or kidney disease, or to horses under stress from extreme heat, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, or high altitude. Protect treated horses from temperature extremes. Some horses, although apparently deeply sedated, may still respond to external stimuli. Routine safety measures should be employed to protect practitioners and handlers. Allowing the horse to stand quietly for 5 minutes before administration and for 10–15 minutes after injection may improve the response to Dormosedan®.</p>
<p>Dormosedan® is a potent α<span class="Sub">2</span>-agonist, and extreme caution should be exercised in its use with other sedative or analgesic drugs for they may produce additive effects.</p>
<p>When using any analgesic to help alleviate <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, a complete physical examination and diagnostic work-up are necessary to determine the etiology of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Food and water should be withheld until the sedative effect of Dormosedan® has worn off.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS: </span>Occasional reports of anaphylactic-like reactions have been received, including 1 or more ofthe following: <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4077979" conceptname="Skin plaque">skin plaques</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the upper airways, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">trembling</span>, recumbency, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="Bold">The use of epinephrine should be avoided since epinephrine may potentiate the effects of α<span class="Sub">2</span>-agonists. </span>Reports of mild adverse reactions have resolved uneventfully without treatment. Severe adverse reactions should be treated symptomatically. As with all α<span class="Sub">2</span>-agonists, the potential for isolated cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> exist, including paradoxical response (excitation).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<p class="First"><span class="Bold">SIDE EFFECTS: </span>Horses treated with Dormosedan® exhibit <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> routinely occurs 1 minute after injection. The relationship between <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> is consistent with an adaptive baroreceptor response to the increased pressure and inconsistent with a primary drug-induced <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>. <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">Piloerection</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, and slight muscle <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> are frequently seen after administration. Partial transient penis prolapse may be seen. Partial AV and SA blocks may occur with decreased heart and <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rates</span>. Urination typically occurs during recovery at about 45–60 minutes posttreatment, depending on dosage. <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Incoordination</span> or <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">staggering</span> is usually seen only during the first 3–5 minutes after injection, until animals have secured a firm footing.</p>
<p>Because of continued lowering of the head during sedation, mucus discharges from the nose and, occasionally, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the head and face may be seen. Holding the head in a slightly elevated position generally prevents these effects.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">OVERDOSAGE: </span>Detomidine hydrochloride is tolerated in horses at up to 200 mcg/kg of body weight (10 times the low dosage and 5 times the high dosage). In safety studies in horses, detomidine hydrochloride at 400 mcg/kg of body weight administered daily for 3 consecutive days produced microscopic foci of <span class="product-label-link" type="condition" conceptid="4354249" conceptname="Myocardial necrosis">myocardial necrosis</span> in 1 of 8 horses.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">DOSAGE AND ADMINISTRATION:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold Italics">For Sedation: </span>Administer Dormosedan® IV or IM at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of sedation required. Onset of sedative effects should be reached within 2–4 minutes after IV administration and 3–5 minutes after IM administration. Twenty mcg/kg will provide 30–90 minutes of sedation and 40 mcg/kg will provide approximately 90 minutes to 2 hours of sedation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Bold Italics">For <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span>: </span>Administer Dormosedan® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> required. Twenty mcg/kg will usually begin to take effect in 2–4 minutes and provide 30–45 minutes of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. The 40 mcg/kg dose will also begin to take effect in 2–4 minutes and provide 45–75 minutes of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<p class="First"><span class="Bold Italics">For Both Sedation and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span>: </span>Administer Dormosedan® IV at the rates of 20 or 40 mcg detomidine hydrochloride per kg of body weight (0.2 or 0.4 mL of Dormosedan® per 100 kg or 220 lb), depending on the depth and duration of sedation and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> required.</p>
<p><span class="Bold">Before and after injection, the animal should be allowed to rest quietly.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">STORAGE: </span>Store at controlled room temperature 15°–30°C (59°–86°F) in the absence of light.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<p class="First"><span class="Bold">HOW SUPPLIED: </span>Dormosedan® is supplied in 5- and 20-mL multidose vials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">NADA #140-862, Approved by FDA</p>
<p><span class="Italics">Manufactured by:</span><br><span class="Bold">ORION<br>PHARMA<br>Orion Corporation</span><br>Espoo, Finland</p>
<p>Distributed by:<br>Zoetis Inc.<br>Kalamazoo, Ml 49007</p>
<p>Revised: January 2013</p>
<p>107224US-10<br>Made in Finland</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 5 mL Vial Carton</h1>
<p class="First"><span class="Bold">DORMOSEDAN</span><span class="Sup">®</span><br><span class="Bold">(detomidine hydrochloride)</span><br><span class="Italics">Sedative and Analgesic For Use in Horses Only<br>Sterile Solution—10 mg/mL</span></p>
<p><span class="Bold">Caution: </span>Federal law restricts this drug to use by or on the<br>order of a licensed veterinarian.</p>
<p><span class="Bold Italics">Net Contents: 5 mL</span><br>NADA #140-862, Approved by FDA</p>
<p><span class="Bold">ORION<br>PHARMA</span></p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="Principal Display Panel - 5 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0effd774-601f-4019-a1f3-350e47835967&amp;name=dormosedan-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 mL Vial Carton</h1>
<p class="First"><span class="Bold">DORMOSEDAN</span><span class="Sup">®</span><br><span class="Bold">(detomidine hydrochloride)</span><br><span class="Italics">Sedative and Analgesic For Use in Horses Only<br>Sterile Solution—10 mg/mL</span></p>
<p><span class="Bold">Caution: </span>Federal law restricts this drug to use by<br> or on the order of a licensed veterinarian.</p>
<p><span class="Bold Italics">Net Contents: 20 mL</span><br>NADA #140-862, Approved by FDA</p>
<p><span class="Bold">ORION<br>PHARMA</span></p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="Principal Display Panel - 20 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0effd774-601f-4019-a1f3-350e47835967&amp;name=dormosedan-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DORMOSEDAN  		
					STERILE</strong><br><span class="contentTableReg">detomidine hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-6290</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>detomidine hydrochloride</strong> (detomidine) </td>
<td class="formItem">detomidine</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">5.9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-6290-1</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54771-6290-2</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA140862</td>
<td class="formItem">12/06/1989</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Zoetis Inc.
							(828851555)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Orion Corporation</td>
<td class="formItem"></td>
<td class="formItem">539763727</td>
<td class="formItem">MANUFACTURE, API MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>efc841d0-7ba2-4c53-a7f8-4435780d4f80</div>
<div>Set id: 0effd774-601f-4019-a1f3-350e47835967</div>
<div>Version: 1</div>
<div>Effective Time: 20140828</div>
</div>
</div> <div class="DistributorName">Zoetis Inc.</div></p>
</body></html>
